← Leaderboards
Beth Baseler
Leidos Biomedical Research, Inc.
$335,223,481
Attributed
$335,223,481
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $169.6M · FY2017–25$200M$150M$100M$50M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$335,223,481 · 2
By mechanism
N01$335,223,481 · 2
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- Elizabeth Baseler$40,046,035
- Calvin Proffitt$24,262,802
Others in their field
Other Emerging Leaders on “Covid-19”
- Sonia M Thomas · Research Triangle Institute$750,724,872
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$156,512,266
- Mark Marino · Venturewell$49,985,567
- Theresa Engel · Leidos Biomedical Research, Inc.$36,854,858
Research focus
Covid-19SafetyPlacebosFundingAfricaTherapeutic EvaluationClinical ResearchRandomizedNational Institute Of Allergy And Infectious DiseaseProtocols DocumentationDisease ProgressionCoronavirusEbola VirusCommunicable DiseasesSiteAdultPreventPrimary EndpointResearch InfrastructureCountryConsentFutureInternationalEbola Vaccines
Grant awards (17)
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH$5,946,332
N01 · FY2025 · AI · contact PI
Ebola Virus and Other Infectious Diseases in DRC and other Countries in Africa (Infrastructure and Capacity)$15,813
N01 · FY2025 · AI · contact PI
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH$13,721,004
N01 · FY2024 · AI · contact PI
NIAID BIG EFFECT TRIAL (BET) FOR COVID-19$22,000,016
N01 · FY2022 · AI · contact PI
The Adaptive COVID-19 Treatment Trial (ACTT)$25,075,500
N01 · FY2021 · AI · contact PI
NIAID BIG EFFECT TRIAL (BET) FOR COVID-19$24,161,705
N01 · FY2021 · AI · contact PI
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH$67,359,812
N01 · FY2020 · CA · contact PI
The Adaptive COVID-19 Treatment Trial (ACTT)$40,199,082
N01 · FY2020 · CA · contact PI
NIAID BIG EFFECT TRIAL (BET) FOR COVID-19$25,810,387
N01 · FY2020 · CA · contact PI
The Adaptive COVID-19 Treatment Trial (ACTT)$18,166,213
N01 · FY2020 · CA · contact PI
ON BEHALF OF DCR FACILITATE THE CONDUCT OF AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENTS WITH COVID-19 INFECTION (10,000 SUBJECTS).$18,109,529
N01 · FY2020 · CA · contact PI
Ebola Virus and Other Infectious Diseases in DRC and other Countries in Africa (Infrastructure and Capacity)$13,043,916
N01 · FY2019 · CA · contact PI
Ebola Virus and Other Infectious Diseases in DRC and other Countries in Africa (PREVAC and/or PREVAC like initiative)$22,470,677
N01 · FY2018 · CA · contact PI
Ebola Virus and Other Infectious Diseases in DRC and other Countries in Africa (Infrastructure and Capacity)$1,981,690
N01 · FY2018 · CA · contact PI
IGF::OT::IGF NS IDIQ: VIRAL AND HEMORRHAGIC FEVERS: EBOLA$24,799
N01 · FY2018 · CA · contact PI
Ebola Virus and Other Emerging & Re-emerging Infectious Diseases$30,337,006
N01 · FY2017 · CA · contact PI
HIV CLINICAL RESEARCH IN WEST AFRICA$6,800,000
N01 · FY2017 · CA · contact PI